---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000100"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:34:23.549340+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M

## Summary
- Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.
- GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.
- Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.
- New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.
- 2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%.

## SEC filing metadata
- accession: 0001396814-25-000100
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/0001396814-25-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000100
- JSON: https://secwatch.observer/filing/0001396814-25-000100.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.